Opko Health, Inc.

305 articles about Opko Health, Inc.

• 

  Pfizer, OPKO One Step Closer to Approval of Pediatric Growth Hormone Deficiency Drug Somatrogon

  1/4/2021

  Pfizer and OPKO Health are one step closer to receiving approval for their jointly developed pediatric growth hormone deficiency drug, somatrogon, after the U.S. FDA recently accepted the companies’ regulatory submission for the therapy.

• OPKO Health to Participate in Three Upcoming Investment Conferences

  11/11/2020

  OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.

• OPKO Health Reports 2020 Third Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  10/29/2020

  OPKO Health, Inc. reports business highlights and financial results for the three months ended September 30, 2020.

• OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020

  10/13/2020

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 29 th beginning at 4:30 p.m. Eastern time. CONFERENCE

• 

  Clinical Catch-Up: October 5-9

  10/12/2020

  It was a moderately busy week for clinical trial news. Here’s a look.

• Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

  10/8/2020

  Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency, met its primary endpoint of improved treatment burden compared to GENOTROPIN® for injection administered once-daily.

• 

  Pfizer and OPKO's Growth Hormone Drug Effective in Late-Stage Trial

  10/8/2020

  Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency.

• OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

  9/15/2020

  OPKO Health, Inc. announces the initiation of a Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19.

• OPKO Health to Participate in Two September 2020 Investment Conferences

  9/2/2020

  OPKO Health, Inc. announced that management will be participating in two upcoming virtual investor conferences.

• OPKO Health to Participate in BTIG Virtual Biotechnology Conference

  8/5/2020

  OPKO Health, Inc. announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 9:00 a.m. Eastern time.

• OPKO Health Reports 2020 Second Quarter Business Highlights and Financial ResultsConference call begins at 4:45 p.m. Eastern time today

  7/30/2020

  OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2020.

• OPKO Health to Report Second Quarter 2020 Financial Results on July 30, 2020

  7/27/2020

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 30, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on July 30 beginning at 4:45 p.m. Eastern time. CONFERENCE CALL &amp; WEBCA

• OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency

  6/9/2020

  OPKO Health Inc. announced that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD.

• FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients

  6/1/2020

  OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE ® as a treatment for patients with mild-to-moderate COVID-19.  The trial, entitled “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of R AYALDEE (calcifediol) E xtended-relea s e C aps u l e s to Treat Symptomatic Patients Infected with SA

• OPKO Health to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/27/2020

  OPKO Health, Inc. announced that management will be participating in the Jefferies Virtual Healthcare Conference being held June 2-4, 2020.

• OPKO Health Reports 2020 First Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  5/6/2020

  OPKO Health, Inc. reports business highlights and financial results for the three months ended March 31, 2020.

• OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020

  4/30/2020

  OPKO Health, Inc. plans to report operating and financial results for the three months ended March 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, May 6, 2020.

• Somatrogon Phase 3 Pediatric Trial Results will be presented on June 8 at ENDO Online 2020

  4/22/2020

  OPKO Health, Inc. provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency.

• OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies

  3/25/2020

  OPKO Health, Inc. (NASDAQ: OPK) today reported interim results from an ongoing Phase 4 clinical trial comparing RAYALDEE® with three common treatment regimens for secondary hyperparathyroidism (SHPT)

• OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  2/26/2020

  OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2019..